AGNC vs ARE

AGNC exhibits severe financial health concerns, as evidenced by a Piotroski F-Score of 3/9 (indicating weak fundamentals) and a missing Altman Z-Score, which raises unquantified distress risk. Despite a high intrinsic value estimate of $43.37 and a Graham Number of $17.64, the stock trades at $10.23, suggesting a potential undervaluation—however, this is undermined by extreme leverage (Debt/Equity: 6.89), near-zero liquidity (Current Ratio: 0.18), and a 97.96% payout ratio. The recent insider selling of $11.43M over six months signals strong bearish sentiment, while earnings have consistently missed expectations in the last four quarters. The 52-week range of $7.85–$12.19 reflects high volatility and lack of sustained momentum.

The deterministic health scores paint a deeply concerning picture, with a Piotroski F-Score of just 2/9 indicating severe financial weakness. Despite a high dividend yield of 8.06%, the payout ratio of 689.47% is unsustainable, and earnings have collapsed, reflected in a negative forward P/E of -746.12 and a YoY EPS decline of -258.6%. While the Price/Book of 0.61 suggests potential value, persistent revenue declines, deteriorating profitability, and a bearish technical trend (0/100) signal significant underlying distress. The lack of analyst price targets and insider buying further undermines confidence in a near-term turnaround.